(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Giga, GlycoMimetics, and Snap.

The three biggest losers today are Republic First Bancorp, Galmed Pharmaceuticals Ltd., and BioNTech SE.

Winners today

1. Giga (GIGA) – 17.61%

Giga-tronics Incorporated, together with its subsidiaries, develops and manufactures electronics equipment for military test and airborne operational applications in the United States and internationally. It operates through two segments, Microsource and the Giga-tronics Division. The company develops microwave components; Band Reject Filters for RADAR/EW (electronic warfare) for solving interference problems in RADAR/EW applications, as well as low noise oscillators used in shipboard and land-based self-protection systems; and RADAR filters for military fighter jet aircraft. It also designs, manufactures, and markets functional test systems for the RADAR/EW equipment of the defense electronics market. The company serves prime defense contractors, the armed services, and research institutes. Giga-tronics Incorporated was incorporated in 1980 and is headquartered in Dublin, California.

NASDAQ ended the session with Giga rising 17.61% to $0.30 on Monday while NASDAQ rose 1.2% to $13,567.98.

Earnings Per Share

As for profitability, Giga has a trailing twelve months EPS of $-2.92.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -153.4%.

Yearly Top and Bottom Value

Giga’s stock is valued at $0.30 at 17:32 EST, way below its 52-week high of $2.39 and way above its 52-week low of $0.09.

Moving Average

Giga’s value is way above its 50-day moving average of $0.22 and way under its 200-day moving average of $0.43.

More news about Giga.

2. GlycoMimetics (GLYC) – 13.6%

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

NASDAQ ended the session with GlycoMimetics jumping 13.6% to $1.42 on Monday while NASDAQ jumped 1.2% to $13,567.98.

Earnings Per Share

As for profitability, GlycoMimetics has a trailing twelve months EPS of $-0.75.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -67.65%.

Moving Average

GlycoMimetics’s value is under its 50-day moving average of $1.50 and way under its 200-day moving average of $1.83.

More news about GlycoMimetics.

3. Snap (SNAP) – 11.92%

Snap Inc. operates as a technology company in North America, Europe, and internationally. The company offers Snapchat, a visual messaging application with various tabs, such as camera, visual messaging, snap map, stories, and spotlight that enable people to communicate visually through short videos and images. It also provides Spectacles, an eyewear product that connects with Snapchat and captures photos and video from a human perspective; and advertising products, including AR ads and Snap ads comprises a single image or video ads, story ads, collection ads, dynamic ads, and commercials. The company was formerly known as Snapchat, Inc. and changed its name to Snap Inc. in September 2016. Snap Inc. was founded in 2010 and is headquartered in Santa Monica, California.

NYSE ended the session with Snap jumping 11.92% to $9.72 on Monday, after two consecutive sessions in a row of losses. NYSE jumped 1.05% to $15,484.50, after two sequential sessions in a row of losses, on what was an all-around up trend exchanging session today.

Earnings Per Share

As for profitability, Snap has a trailing twelve months EPS of $-0.85.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -45.52%.

Volume

Today’s last reported volume for Snap is 42409100 which is 76.57% above its average volume of 24018000.

Yearly Top and Bottom Value

Snap’s stock is valued at $9.72 at 17:32 EST, way below its 52-week high of $13.89 and way higher than its 52-week low of $7.33.

More news about Snap.

4. Castle Biosciences (CSTL) – 9.05%

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary 35-GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

NASDAQ ended the session with Castle Biosciences rising 9.05% to $13.50 on Monday while NASDAQ rose 1.2% to $13,567.98.

Earnings Per Share

As for profitability, Castle Biosciences has a trailing twelve months EPS of $-3.05.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -22.2%.

Volume

Today’s last reported volume for Castle Biosciences is 141647 which is 49.02% below its average volume of 277859.

More news about Castle Biosciences.

5. Groupon (GRPN) – 8.47%

Groupon, Inc., together with its subsidiaries, operates a marketplace that connects consumers to merchants. It operates in two segments, North America and International. The company sells goods or services on behalf of third-party merchants; and first-party goods inventory. It serves customers through its mobile applications and websites. The company was formerly known as ThePoint.com, Inc. and changed its name to Groupon, Inc. in October 2008. Groupon, Inc. was incorporated in 2008 and is headquartered in Chicago, Illinois.

NASDAQ ended the session with Groupon jumping 8.47% to $13.79 on Monday, after three successive sessions in a row of gains. NASDAQ jumped 1.2% to $13,567.98, after two consecutive sessions in a row of losses, on what was an all-around up trend trading session today.

Earnings Per Share

As for profitability, Groupon has a trailing twelve months EPS of $-5.84.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -309.27%.

More news about Groupon.

6. BlackBerry (BB) – 7.78%

BlackBerry Limited provides intelligent security software and services to enterprises and governments worldwide. The company operates through three segments: Cybersecurity, IoT, and Licensing and Other. The company offers CylancePROTECT, an endpoint protection platform and mobile threat defense solution; CylanceOPTICS, an endpoint detection and response solution; CylanceGUARD, a managed detection and response solution; CylanceGATEWAY, an AI-empowered zero-trust network access solution; CylancePERSONA, a user and entity behavior analytics solution; BlackBerry unified endpoint management, a central software component for secure communications platform; BlackBerry Dynamics, a development platform and secure container for mobile applications; and BlackBerry Workspaces solutions. It also provides BlackBerry SecuSUITE, a multi-OS voice and text messaging solution; BlackBerry AtHoc and BlackBerry Alert, which are secure and networked critical event management solutions; BlackBerry QNX that offers real-time operating systems, hypervisors, middleware, development tools, and professional services; BlackBerry Certicom, a cryptography and key management product; BlackBerry Radar, an asset monitoring solution; and BlackBerry IVY, an intelligent vehicle data platform. In addition, the company is involved in the patent licensing and legacy service access fees business. The company was formerly known as Research In Motion Limited and changed its name to BlackBerry Limited in July 2013. BlackBerry Limited was incorporated in 1984 and is headquartered in Waterloo, Canada.

NYSE ended the session with BlackBerry jumping 7.78% to $3.74 on Monday, after four sequential sessions in a row of losses. NYSE jumped 1.05% to $15,484.50, after two sequential sessions in a row of losses, on what was an all-around positive trend exchanging session today.

Earnings Per Share

As for profitability, BlackBerry has a trailing twelve months EPS of $-0.98.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -51.13%.

Volatility

BlackBerry’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.69%, a negative 2.39%, and a positive 2.78%.

BlackBerry’s highest amplitude of average volatility was 0.91% (last week), 2.56% (last month), and 2.78% (last quarter).

More news about BlackBerry.

7. FuboTV (FUBO) – 7.68%

fuboTV Inc. operates a live TV streaming platform for live sports, news, and entertainment content in the United States and internationally. Its fuboTV platform allows customers to access content through streaming devices, as well as on SmartTVs, computers, mobile phones, and tablets. The company is headquartered in New York, New York.

NYSE ended the session with FuboTV rising 7.68% to $2.52 on Monday while NYSE jumped 1.05% to $15,484.50.

Earnings Per Share

As for profitability, FuboTV has a trailing twelve months EPS of $-1.53.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -67.06%.

Sales Growth

FuboTV’s sales growth is 33.4% for the ongoing quarter and 19% for the next.

More news about FuboTV.

8. 3D Systems (DDD) – 7.49%

3D Systems Corporation provides 3D printing and digital manufacturing solutions in the Americas, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company offers 3D printers technologies, such as stereolithography, selective laser sintering, direct metal printing, multi jet printing, color jet printing, polymer extrusion, and extrusion and SLA based bioprinting that transform digital data input generated by 3D design software, computer aided design (CAD) software, or other 3D design tools into printed parts. It also develops, blends, and markets various print materials, such as plastic, nylon, metal, composite, elastomeric, wax, polymeric dental materials, and biocompatible materials. In addition, the company provides digital design tools, including software, scanners, and haptic devices, as well as solutions for product design, simulation, mold and die design, 3D scan-to-print, reverse engineering, production machining, metrology, and inspection and manufacturing workflows under the Geomagic brand. Further, it offers 3D Sprint and 3DXpert, a proprietary software to prepare and optimize CAD data and manage the additive manufacturing processes, which provides automated support building and placement, build platform management, print simulation, and print queue management; and Bioprint Pro, a software solution that allows researchers to design and bioprint repeatable experiments. Additionally, the company provides maintenance and training services; manufacturing services; and software and precision healthcare services. It primarily serves companies and small and midsize businesses in medical, dental, automotive, aerospace, durable goods, government, defense, technology, jewelry, electronic, education, consumer goods, energy, biotechnology, and other industries through direct sales force, channel partners, and appointed distributors. 3D Systems Corporation was founded in 1986 and is headquartered in Rock Hill, South Carolina.

NYSE ended the session with 3D Systems rising 7.49% to $4.16 on Monday, after three successive sessions in a row of losses. NYSE rose 1.05% to $15,484.50, after two sequential sessions in a row of losses, on what was an all-around positive trend trading session today.

Earnings Per Share

As for profitability, 3D Systems has a trailing twelve months EPS of $-0.94.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -16.22%.

Yearly Top and Bottom Value

3D Systems’s stock is valued at $4.16 at 17:32 EST, way below its 52-week high of $12.67 and above its 52-week low of $3.81.

Volatility

3D Systems’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.84%, a negative 1.31%, and a positive 2.72%.

3D Systems’s highest amplitude of average volatility was 3.64% (last week), 3.21% (last month), and 2.72% (last quarter).

More news about 3D Systems.

9. 3D Systems (DDD) – 7.49%

3D Systems Corporation provides 3D printing and digital manufacturing solutions in the Americas, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company offers 3D printers technologies, such as stereolithography, selective laser sintering, direct metal printing, multi jet printing, color jet printing, polymer extrusion, and extrusion and SLA based bioprinting that transform digital data input generated by 3D design software, computer aided design (CAD) software, or other 3D design tools into printed parts. It also develops, blends, and markets various print materials, such as plastic, nylon, metal, composite, elastomeric, wax, polymeric dental materials, and biocompatible materials. In addition, the company provides digital design tools, including software, scanners, and haptic devices, as well as solutions for product design, simulation, mold and die design, 3D scan-to-print, reverse engineering, production machining, metrology, and inspection and manufacturing workflows under the Geomagic brand. Further, it offers 3D Sprint and 3DXpert, a proprietary software to prepare and optimize CAD data and manage the additive manufacturing processes, which provides automated support building and placement, build platform management, print simulation, and print queue management; and Bioprint Pro, a software solution that allows researchers to design and bioprint repeatable experiments. Additionally, the company provides maintenance and training services; manufacturing services; and software and precision healthcare services. It primarily serves companies and small and midsize businesses in medical, dental, automotive, aerospace, durable goods, government, defense, technology, jewelry, electronic, education, consumer goods, energy, biotechnology, and other industries through direct sales force, channel partners, and appointed distributors. 3D Systems Corporation was founded in 1986 and is headquartered in Rock Hill, South Carolina.

NYSE ended the session with 3D Systems jumping 7.49% to $4.16 on Monday, after three successive sessions in a row of losses. NYSE jumped 1.05% to $15,484.50, after two sequential sessions in a row of losses, on what was an all-around bullish trend exchanging session today.

Earnings Per Share

As for profitability, 3D Systems has a trailing twelve months EPS of $-0.94.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -16.22%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

3D Systems’s EBITDA is -58.28.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, 3D Systems’s stock is considered to be overbought (>=80).

Yearly Top and Bottom Value

3D Systems’s stock is valued at $4.16 at 17:32 EST, way under its 52-week high of $12.67 and above its 52-week low of $3.81.

More news about 3D Systems.

10. American Public Education (APEI) – 7.48%

American Public Education, Inc., together with its subsidiaries, provides online and campus-based postsecondary education and career learning. It operates through three segments: American Public University System, Rasmussen University, and Hondros College of Nursing. The company offers 136 degree programs and 115 certificate programs in various fields of study, including nursing, public health, public administration, and business administration. It also provides nursing-and health sciences-focused postsecondary education, diploma in practical nursing, and an associate degree in nursing. The company was incorporated in 1991 and is headquartered in Charles Town, West Virginia.

NASDAQ ended the session with American Public Education rising 7.48% to $4.74 on Monday, after two successive sessions in a row of losses. NASDAQ jumped 1.2% to $13,567.98, after two consecutive sessions in a row of losses, on what was an all-around positive trend trading session today.

Earnings Per Share

As for profitability, American Public Education has a trailing twelve months EPS of $-3.67.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -22.39%.

Sales Growth

American Public Education’s sales growth is 1.8% for the current quarter and negative 0.6% for the next.

Volume

Today’s last reported volume for American Public Education is 34615 which is 43.75% below its average volume of 61545.

Revenue Growth

Year-on-year quarterly revenue growth declined by 1.6%, now sitting on 598.88M for the twelve trailing months.

More news about American Public Education.

Losers Today

1. Republic First Bancorp (FRBK) – -23.08%

Republic First Bancorp, Inc. operates as the holding company for Republic First Bank that provides a range of credit and depository banking products and services to individuals and businesses. It accepts consumer and commercial deposit, checking, interest-bearing demand, money market, savings, sweep, and individual retirement accounts, as well as certificates of deposit. The company also offers secured and unsecured commercial, real estate, construction and land development, automobile, and home improvement loans; mortgages, home equity and overdraft lines of credit, and other products; and lockbox services. As of April 5, 2022, it operated 34 offices located in Atlantic, Burlington, Camden, and Gloucester counties in New Jersey; Bucks, Delaware, Montgomery, and Philadelphia counties in Pennsylvania; and New York County in New York. Republic First Bancorp, Inc. was founded in 1987 and is based in Philadelphia, Pennsylvania.

NASDAQ ended the session with Republic First Bancorp dropping 23.08% to $0.10 on Monday while NASDAQ jumped 1.2% to $13,567.98.

Earnings Per Share

As for profitability, Republic First Bancorp has a trailing twelve months EPS of $0.17.

PE Ratio

Republic First Bancorp has a trailing twelve months price to earnings ratio of 0.59. Meaning, the purchaser of the share is investing $0.59 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.96%.

Volume

Today’s last reported volume for Republic First Bancorp is 1665 which is 99.68% below its average volume of 528215.

Moving Average

Republic First Bancorp’s worth is way below its 50-day moving average of $0.38 and way under its 200-day moving average of $1.19.

Sales Growth

Republic First Bancorp’s sales growth is negative 34.6% for the present quarter and negative 49% for the next.

More news about Republic First Bancorp.

2. Galmed Pharmaceuticals Ltd. (GLMD) – -8.89%

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

NASDAQ ended the session with Galmed Pharmaceuticals Ltd. sliding 8.89% to $0.41 on Monday while NASDAQ rose 1.2% to $13,567.98.

Earnings Per Share

As for profitability, Galmed Pharmaceuticals Ltd. has a trailing twelve months EPS of $-6.23.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -73%.

Yearly Top and Bottom Value

Galmed Pharmaceuticals Ltd.’s stock is valued at $0.41 at 17:32 EST, way under its 52-week high of $5.63 and way above its 52-week low of $0.29.

More news about Galmed Pharmaceuticals Ltd..

3. BioNTech SE (BNTX) – -6.33%

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

NASDAQ ended the session with BioNTech SE sliding 6.33% to $97.02 on Monday, after three consecutive sessions in a row of losses. NASDAQ jumped 1.2% to $13,567.98, after two sequential sessions in a row of losses, on what was an all-around up trend exchanging session today.

Earnings Per Share

As for profitability, BioNTech SE has a trailing twelve months EPS of $19.2.

PE Ratio

BioNTech SE has a trailing twelve months price to earnings ratio of 5.05. Meaning, the purchaser of the share is investing $5.05 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.82%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 94.8%, now sitting on 9.18B for the twelve trailing months.

Sales Growth

BioNTech SE’s sales growth is negative 41.7% for the present quarter and negative 49.1% for the next.

Volatility

BioNTech SE’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.13%, a negative 0.19%, and a positive 1.92%.

BioNTech SE’s highest amplitude of average volatility was 1.26% (last week), 1.93% (last month), and 1.92% (last quarter).

More news about BioNTech SE.

4. Extreme Networks (EXTR) – -6.07%

Extreme Networks, Inc. provides software-driven networking solutions worldwide. It designs, develops, and manufactures wired and wireless network infrastructure equipment; and develops software for network management, policy, analytics, security, and access controls. The company offers ExtremeCloud IQ, an ML/AI powered, wired, and wireless cloud network management solution that offers advanced visibility and control over users, devices, and applications; ExtremeCloud IQ – Site Engine that provides task automation, access control, granular visibility with real-time analytics and multi-vendor device management; and ExtremeCloud IQ Essentials offers WIPS, location services, IoT, and guest management services. It also provides wireless access point products; ExtremeSwitching portfolio that includes access edge products that offer physical presentations along with options to deliver Ethernet or convergence-friendly Power-over-Ethernet (POE), including high-power universal POE; aggregation/core switches designed to address aggregation, top-of-rack, and campus core environments; and data center switches and routers. In addition, the company offers cloud native platforms and applications for service providers; and customer support and services. It markets and sells its products through distributors, resellers, and field sales organizations to healthcare, education, government, manufacturing, retail, and hospitality markets. Extreme Networks, Inc. was incorporated in 1996 and is headquartered in Morrisville, North Carolina.

NASDAQ ended the session with Extreme Networks dropping 6.07% to $22.92 on Monday while NASDAQ rose 1.2% to $13,567.98.

Earnings Per Share

As for profitability, Extreme Networks has a trailing twelve months EPS of $0.55.

PE Ratio

Extreme Networks has a trailing twelve months price to earnings ratio of 41.67. Meaning, the purchaser of the share is investing $41.67 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 75.4%.

More news about Extreme Networks.

5. First Interstate BancSystem (FIBK) – -4.84%

First Interstate BancSystem, Inc. operates as the bank holding company for First Interstate Bank that provides range of banking products and services in the United States. It offers various traditional depository products, including checking, savings, and time deposits; and repurchase agreements primarily for commercial and municipal depositors. The company also offers real estate loans comprising commercial real estate, construction, residential, agricultural, and other real estate loans; consumer loans comprising direct personal loans, credit card loans and lines of credit, and indirect loans; variable and fixed rate commercial loans for small and medium-sized manufacturing, wholesale, retail, and service businesses for working capital needs and business expansions; and agricultural loans. In addition, it provides a range of trust, employee benefit, investment management, insurance, agency, and custodial services to individuals, businesses, and nonprofit organizations. Further, the company offers marketing, credit review, loan servicing, credit cards issuance and servicing, mortgage loan sales and servicing, indirect consumer loan purchasing and processing, loan collection services, and other operational services, as well as online and mobile banking services. It serves individuals, businesses, municipalities, and other entities in various industries, including agriculture, construction, education, energy, governmental services, healthcare, hospitality, housing, mining, professional services, real estate development, retail, technology, tourism, and wholesale trade. As of December 31, 2021, it operated 147 banking offices, including detached drive-up facilities in communities across Idaho, Montana, Oregon, South Dakota, Washington, and Wyoming. The company was incorporated in 1971 and is headquartered in Billings, Montana.

NASDAQ ended the session with First Interstate BancSystem dropping 4.84% to $22.98 on Monday, after two successive sessions in a row of losses. NASDAQ jumped 1.2% to $13,567.98, after two successive sessions in a row of losses, on what was an all-around bullish trend exchanging session today.

Earnings Per Share

As for profitability, First Interstate BancSystem has a trailing twelve months EPS of $2.85.

PE Ratio

First Interstate BancSystem has a trailing twelve months price to earnings ratio of 8.06. Meaning, the purchaser of the share is investing $8.06 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.22%.

More news about First Interstate BancSystem.

6. Novavax (NVAX) – -4.54%

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, Adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also focusing on products candidates for respiratory syncytial virus and malaria. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

NASDAQ ended the session with Novavax sliding 4.54% to $6.73 on Monday while NASDAQ rose 1.2% to $13,567.98.

Earnings Per Share

As for profitability, Novavax has a trailing twelve months EPS of $-6.75.

More news about Novavax.

7. TherapeuticsMD (TXMD) – -4.53%

TherapeuticsMD, Inc. operates as a pharmaceutical company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

NASDAQ ended the session with TherapeuticsMD sliding 4.53% to $2.43 on Monday while NASDAQ rose 1.2% to $13,567.98.

Earnings Per Share

As for profitability, TherapeuticsMD has a trailing twelve months EPS of $3.28.

PE Ratio

TherapeuticsMD has a trailing twelve months price to earnings ratio of 0.74. Meaning, the purchaser of the share is investing $0.74 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1134.2%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, TherapeuticsMD’s stock is considered to be overbought (>=80).

Moving Average

TherapeuticsMD’s worth is way below its 50-day moving average of $3.45 and way below its 200-day moving average of $4.12.

Sales Growth

TherapeuticsMD’s sales growth is negative 97.6% for the ongoing quarter and negative 47.9% for the next.

More news about TherapeuticsMD.

8. Moderna (MRNA) – -4.47%

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

NASDAQ ended the session with Moderna falling 4.47% to $93.91 on Monday while NASDAQ rose 1.2% to $13,567.98.

Earnings Per Share

As for profitability, Moderna has a trailing twelve months EPS of $2.75.

PE Ratio

Moderna has a trailing twelve months price to earnings ratio of 34.15. Meaning, the purchaser of the share is investing $34.15 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.91%.

Yearly Top and Bottom Value

Moderna’s stock is valued at $93.91 at 17:32 EST, under its 52-week low of $95.02.

More news about Moderna.

9. Nikola (NKLA) – -4.26%

Nikola Corporation operates as a technology innovator and integrator that develops energy and transportation solutions. It operates through two business units, Truck and Energy. The Truck business unit develops and commercializes battery electric vehicles (BEV) and hydrogen fuel cell electric vehicles (FCEV) to the trucking sector. The Energy business unit develops and constructs a network of hydrogen fueling stations; and offers BEV charging solutions for its FCEV and BEV customers, as well as other third-party customers. The company also assembles, integrates, and commissions its vehicles in collaboration with its business partners and suppliers. Nikola Corporation founded in 2015 and is headquartered in Phoenix, Arizona.

NASDAQ ended the session with Nikola falling 4.26% to $1.24 on Monday while NASDAQ jumped 1.2% to $13,567.98.

Earnings Per Share

As for profitability, Nikola has a trailing twelve months EPS of $-1.45.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -132.55%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 46.4% and 64.9%, respectively.

More news about Nikola.

10. Genetic Technologies Ltd (GENE) – -4%

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, and type 2 diabetes. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

NASDAQ ended the session with Genetic Technologies Ltd dropping 4% to $0.69 on Monday while NASDAQ jumped 1.2% to $13,567.98.

Earnings Per Share

As for profitability, Genetic Technologies Ltd has a trailing twelve months EPS of $-0.04.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -85.17%.

Moving Average

Genetic Technologies Ltd’s worth is way under its 50-day moving average of $0.77 and way below its 200-day moving average of $0.98.

Volume

Today’s last reported volume for Genetic Technologies Ltd is 98327 which is 3.17% below its average volume of 101556.

More news about Genetic Technologies Ltd.

Stay up to date with our winners and losers daily report